Teduglutide

Among 19 children on teduglutide over 6 months, median reductions in daily parenteral support energy and fluid volume were 42% and 28 mL/kg/day, with weekly infusion-free nights increasing from 0.5 to 4.; Seventeen (89%) patients reached >20% energy reduction and six (32%) successfully weaned off parenteral support.; Adverse effects included intestinal bleeding in 4 patients (20%) and stomal prolapses in all patients with end-jejunostomies.; Periodic withdrawal (n = 37) led to adverse effects on 84% of occasions, including two unplanned hospitalizations, dehydration in 51%, and diarrhea in 76%.

Gut microbiome α-diversity increased after teduglutide treatment.; T helper 2 cells decreased and regulatory T cells increased, indicating a shift toward an immunoregulatory intestinal environment.; Nutrient-absorbing enterocyte-Top2 and middle clusters expanded, enhancing absorption capacity.; MHC class I/II-expressing enterocyte-Top1 cells declined, potentially modulating immune responses.

Best response (CR or PR) was 64.7% (11/17) including 41.2% CR and 23.5% PR.; At median follow-up of 28 weeks, 10/17 patients were alive.; Most patients had increased albumin levels within 2 months, even among non-responders.; No specific teduglutide-related toxicity was reported.

Coeliac disease should always be investigated in unexplained malabsorption and high-risk individuals due to its high prevalence.; Teduglutide effectively reduces the need for parenteral nutrition in short bowel syndrome, improving quality of life.; Primary care physicians are crucial for early detection and should be part of multidisciplinary teams.; Nutritional support options include oral supplements, enteral nutrition, and parenteral nutrition.

Malabsorption can be selective or global, caused by congenital or acquired disorders in children and adults.; Early recognition is key, using endoscopy with small intestinal biopsies, non-invasive functional tests, and radiological imaging.; Celiac disease should always be investigated in unexplained malabsorption and high-risk individuals.; Nutritional support (oral, enteral, parenteral) is central; teduglutide reduces parenteral nutrition need in short bowel syndrome.

Nutritional rehabilitation is the cornerstone of IF management, with individualized enteral and parenteral nutrition therapy.; Teduglutide promotes mucosal growth and is used medically, but its oral absorption is poor and milk levels are likely very low.; Two breastfed infants had no reported adverse effects during maternal teduglutide use, but long-term data are lacking.; An interdisciplinary team approach is crucial for managing complex IF patients.

Teduglutide-treated patients had higher male prevalence, younger age, longer HPN duration, more jejunocolonic anastomosis, lower IVS volume, and higher weaning from IVS than controls.; Controls had higher percentages of patients deceased or lost to follow up.; Centers treating 10 or more patients with Teduglutide showed higher weaning rates and lower mortality rates.; Clinicians preferentially selected patients with better prognostic indicators for Teduglutide treatment.

What is Teduglutide?

Teduglutide is a recombinant analog of glucagon-like peptide-2 (GLP-2) that acts as a selective GLP-2 receptor agonist. Its primary mechanism involves binding to GLP-2 receptors in the gastrointestinal tract, which stimulates crypt cell proliferation and reduces enterocyte apoptosis, leading to increased intestinal muc

How does Teduglutide work?

GLP-2 receptor agonist that promotes intestinal mucosal growth and absorption; approved for short bowel syndrome.

What is the research status of Teduglutide?

Teduglutide is currently classified as approved, with 365 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Teduglutide?

Teduglutide has a molecular weight of approximately 3752.1 g/mol (formula C164H252N44O55S).